Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03

被引：0
|
作者：
Saura, Cristina
Cortes, Javier
Modi, Shanu
Kim, Sung-Bae
Hamilton, Erika P.
Hurvitz, Sara A.
Krop, Ian E.
Curigliano, Giuseppe
Iwata, Hiroji
Im, Seock-Ah
Herbolsheimer, Pia Maarit
Karnoub, Maha
Gambhire, Dhiraj
Egorov, Anton
Andre, Fabrice
机构：
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Quironsalud Grp, Int Breast Canc Ctr IBCC, Pangaea Oncol, Barcelona, Spain
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Univ Washington, Sch Med, Seattle, WA USA
[7] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[8] Yale Canc Ctr, New Haven, CT USA
[9] Univ Milan, Milan, Italy
[10] IRCCS, European Inst Oncol, Milan, Italy
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst,Natl Univ Hosp, Seoul, South Korea
[13] AstraZeneca, Gaithersburg, MD USA
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Daiichi Sankyo, Basking Ridge, NJ USA
[16] Univ Paris Saclay, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1023
引用
收藏
页数：1
相关论文
共 50 条
  • [1] An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03
    Krop, Ian E.
    Wildiers, Hans
    Hurvitz, Sara A.
    Cortes, Javier
    Im, Seock-Ah
    Iwata, Hiroji
    Andre, Fabrice
    Saura, Cristina
    Modi, Shanu
    Kim, Sung-Bae
    Egorov, Anton
    Mathias, Elton
    Cathcart, Jillian
    Cagnazzo, Antonio
    Cheng, Yingkai
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03
    Hurvitz, S. A.
    Modi, S.
    Li, W.
    Park, Y. H.
    Chung, W.
    Kim, S-B.
    Cortes, J.
    Yamashita, T.
    Pedrini, J.
    Im, S-A.
    Tseng, L-M.
    Harbeck, N.
    Krop, I.
    Curigliano, G.
    Mathias, E.
    Cathcart, J.
    Cagnazzo, A.
    Ashfaque, S.
    Egorov, A.
    Andre, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S335 - S336
  • [3] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Im, Seock-Ah
    Iwata, Hiroji
    Curigliano, Giuseppe
    Kim, Sung-Bae
    Chiu, Joanne Wing-Yan
    Pedrini, Jose Luiz
    Li, Wei
    Yonemori, Kan
    Bianchini, Giampaolo
    Loi, Sherene
    Borges, Giuliano Santos
    Wang, Xian
    Bachelot, Thomas
    Nakatani, Shunsuke
    Ashfaque, Shahid
    Liang, Zhengkang
    Egorov, Anton
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
    Jerusalem, Guy Heinrich Maria
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Gonzalez, Xavier
    Hall, Peter S.
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R. C.
    Sagara, Yasuaki
    Tokunaga, Eriko
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb C.
    Perrin, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [6] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [7] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Saura Manich, C.
    Modi, S.
    Krop, I.
    Park, Y. H.
    Kim, S-B.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Singh, J.
    Yamashita, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
  • [8] Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
    Hurvitz, Sara
    Kim, Sung-Bae
    Chung, Wei-Pang
    Im, Seock-Ah
    Park, Yeon Hee
    Hegg, Roberto
    Kim, Min-Hwan
    Tseng, Ling-Ming
    Petry, Vanessa
    Chung, Chi-Feng
    Iwata, Hiroji
    Hamilton, Erika
    Curigliano, Giuseppe
    Xu, Binghe
    Lee, Caleb
    Liu, Yali
    Cathcart, Jillian
    Bako, Emarjola
    Verma, Sunil
    Cortes, Javier
    CANCER RESEARCH, 2022, 82 (04)
  • [9] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Liu, Yali
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Baselga, Jose
    Krop, Ian E.
    CANCER RESEARCH, 2021, 81 (04)
  • [10] Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic experience
    Hoppenworth, Jenna
    Premji, Sarah
    Smith, Deanne R.
    Taraba, Jodi L.
    Hobday, Timothy J.
    Peethambaram, Prema P.
    Carroll, Jamie
    Ruddy, Kathryn Jean
    O'Sullivan, Ciara Catherine
    Tevaarwerk, Amye Juliet
    Choong, Grace Mei Yee
    Cathcart-Rake, Elizabeth Jane
    Yadav, Siddhartha
    Ellsworth, Lisa
    Rao, Rohit
    Egan, Ashley
    Haddad, Tufia C.
    Goetz, Matthew P.
    Giridhar, Karthik
    Leon-Ferre, Roberto Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345